首页 | 本学科首页   官方微博 | 高级检索  
     

丝裂霉素联合塞来昔布对膀胱癌T24细胞增殖的影响研究
引用本文:孙世宝,盛玉文,于立春,曲更庆,王庆军. 丝裂霉素联合塞来昔布对膀胱癌T24细胞增殖的影响研究[J]. 中国药房, 2013, 0(17): 1566-1568
作者姓名:孙世宝  盛玉文  于立春  曲更庆  王庆军
作者单位:辽宁医学院附属第一医院泌尿外科,辽宁锦州121001
摘    要:目的:研究体外丝裂霉素(MMC)联合塞来昔布对浅表性膀胱癌T24细胞增殖的影响及其可能机制。方法:体外培养浅表性膀胱癌T24细胞,分为MMC[0(对照组)、2、5、10、25、50μmol/L]组及其与塞来昔布(50μmol/L)混合组,每个浓度5个复孔,采用MTT法检测作用24h后细胞的增殖抑制率。采用免疫组化法、实时定量聚合酶链式反应法、酶联免疫吸附测定法检测对照组、MMC(50μmol/L)组和混合[塞来昔布+MMC(50μmol/L)]组作用48h细胞中Bcl-2蛋白、作用24h细胞血管内皮生长因子(VEGF)mRNA的表达及作用96h内VEGF蛋白浓度。结果:MMC能明显抑制细胞增殖(P<0.05),且呈浓度依赖性;塞来昔布能明显增强MMC对细胞的增殖抑制作用(P<0.05);与对照组比较,MMC组和塞来昔布+MMC组细胞中Bcl-2蛋白、VEGF mRNA表达均明显降低(P<0.05),且后2组组间比较有统计学差异(P<0.05);塞来昔布+MMC组细胞中VEGF蛋白浓度随作用时间延长明显降低(P<0.01)。结论:塞来昔布可协同增强MMC抑制T24细胞增殖的作用,其机制可能与降低Bcl-2、VEGFmRNA表达水平和抑制细胞分泌VEGF蛋白作用有关。

关 键 词:膀胱癌T24细胞  丝裂霉素  塞来昔布  增殖抑制率  Bcl-2  血管内皮生长因子  表达

Effects of Mitomycin Combined with Celecoxib on the Proliferation of Bladder Cancer Cell Line T24
SUN Shi-bao,SHENG Yu-wen,YU Li-chun,QU Geng-qing,WANG Qing-jun. Effects of Mitomycin Combined with Celecoxib on the Proliferation of Bladder Cancer Cell Line T24[J]. China Pharmacy, 2013, 0(17): 1566-1568
Authors:SUN Shi-bao  SHENG Yu-wen  YU Li-chun  QU Geng-qing  WANG Qing-jun
Affiliation:(Dept. of Urology Surgery, The First Affiliated Hospital of Liaoning Medical College, Liaoning Jinzhou 121001, China)
Abstract:OBJECTIVE: To investigate the effects of mitomycin (MMC) combined with celecoxib on the proliferation of superficial bladder cancer cell line T24 and the possible mechanism. METHODS: The superficial bladder cancer T24 cell line were cultured in vitro, and divided into MMC groups [0 (control group), 2, 5, 10, 25 and 50 μmol/L] and MMC combined with celecoxib (50 μmol/L) group with each concentration of 5 bores. MTT method was used to detect the proliferation inhibition rate after 24 h. Immunohistochemistry assay, RT-PCR and ELISA method were adopted to detect the expression of Bcl-2 protein after 48 h of treatment and VEGF mRNA after 24 h of treatment and the protein concentration of VEGF within 96 h of treatment in control group, MMC (50 μmol/L) group and mixture [celecoxib+MMC (50 μmol/L)] group. RESULTS: MMC could inhibit the proliferation of T24 cell (P〈0.05), in dose dependent manner; celecoxib could significantly enhance the inhibitory effect of MMC (P〈 0.05). Compared with control group, the expression of Bcl-2 protein and VEGF mRNA were decreased significantly in MMC group and celecoxib+MMC group (P〈0.05); there was statistical significance between the latter 2 groups (P〈0.05). The concentration of VEGF protein in celecoxib+MMC group was decreased significantly statistically with time (P〈0.01). CONCLUSIONS: Celecoxib can collaboratively enhance inhibitory effect of MMC on the proliferation of T24 cell. The mechanism may be related to reducing the expression of Bcl-2 and VEGF mRNA and inhibiting the secretion of VEGF protein.
Keywords:Bladder cancer cell line T24  Mitomycin  Celecoxib  Proliferation inhibition rate  Bcl-2  VEGF  Expression
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号